Group 1 - Encompass Health (EHC) is a strong performer in the Medical sector, with a year-to-date return of approximately 30.3%, significantly outperforming the sector average loss of 3.5% [4] - The Zacks Rank for Encompass Health is 1 (Strong Buy), indicating a positive earnings outlook and strong analyst sentiment, with earnings estimates having increased by 4.4% in the past quarter [3][4] - The Medical sector consists of 998 individual stocks and currently holds a Zacks Sector Rank of 6, reflecting the average performance of stocks within this sector [2] Group 2 - Encompass Health operates within the Medical - Outpatient and Home Healthcare industry, which includes 17 stocks and has a Zacks Industry Rank of 39, with an average gain of 4.9% this year [6] - Another notable stock in the Medical sector is Elanco Animal Health Incorporated (ELAN), which has achieved a 15% increase year-to-date and has a Zacks Rank of 2 (Buy) [5][6] - Both Encompass Health and Elanco Animal Health are highlighted as stocks to watch for continued solid performance in the Medical sector [7]

Company Performance - atai Life Sciences N.V. has returned 81.2% year-to-date, significantly outperforming the average loss of 3.4% in the Medical sector [4] - The Zacks Consensus Estimate for atai Life Sciences N.V.'s full-year earnings has increased by 0.8% over the past three months, indicating improved analyst sentiment [4] - atai Life Sciences N.V. currently holds a Zacks Rank of 2 (Buy), suggesting a favorable earnings outlook [3] Industry Comparison - atai Life Sciences N.V. is part of the Medical - Outpatient and Home Healthcare industry, which has gained approximately 5.1% year-to-date, indicating that atai is performing better than its industry peers [6] - In contrast, Novartis, another outperforming stock in the Medical sector, has increased by 21.3% year-to-date and belongs to the Large Cap Pharmaceuticals industry, which has seen a decline of 1.1% [5][6] - The Medical sector ranks 5 in the Zacks Sector Rank, which includes 16 different groups ranked by the average Zacks Rank of individual companies [2]

Company Overview - Elanco Animal Health Incorporated (ELAN) is currently experiencing significant activity in the options market, particularly with the Jan 16, 2026 $3.00 Call option showing high implied volatility, indicating potential for a major price movement [1] Market Sentiment - The high implied volatility suggests that investors are anticipating a significant price change for Elanco Animal Health shares, which could be driven by an upcoming event [2][4] - Analysts have a mixed outlook on Elanco, with the company holding a Zacks Rank 3 (Hold) in the Medical - Outpatient and Home Healthcare industry, which is in the top 26% of the Zacks Industry Rank [3] Earnings Estimates - Over the past 60 days, there have been no increases in earnings estimates for the current quarter, while six analysts have lowered their estimates, resulting in a decrease of the Zacks Consensus Estimate from earnings of 25 cents per share to 20 cents [3]

LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company (“the Common Shares”) from time to time in accordance with applicable securities laws, representing a ...

Core Viewpoint - Aveanna Healthcare Holdings Inc. has completed the acquisition of Thrive Skilled Pediatric Care, enhancing its position in the pediatric home care market and expanding its service offerings into new states [1][2][3]. Company Overview - Aveanna Healthcare is a diversified home care platform providing services to medically complex, high-cost patient populations, with a presence in 36 states [7]. - The company offers a wide range of healthcare services, including nursing, rehabilitation, therapy, and case management, aimed at providing high-quality, lower-cost alternatives to prolonged hospitalization [7]. Acquisition Details - Thrive SPC is one of the largest independent providers of pediatric home care, operating 23 locations across seven states [2]. - The acquisition is expected to create significant growth opportunities for Aveanna, reinforcing its commitment to clinical excellence and compassionate care [3]. - The deal was financed through a combination of common stock and cash [3]. Strategic Implications - The integration of Thrive SPC is anticipated to enhance Aveanna's existing footprint and introduce its specialized care model into two new states [2][3]. - The acquisition aligns with Aveanna's strategic mission to lead in delivering high-quality care while providing value and clinical innovation to payors and stakeholders [3]. Advisory and Legal Support - Edge Healthcare Partners acted as the financial advisor for Aveanna, while Cantor Fitzgerald & Co. served as the financial advisor for Thrive SPC [4]. - Legal counsel for Aveanna was provided by Bass, Berry & Sims, and Ropes & Gray LLP represented Thrive SPC [4].

Company Overview - Atai Life Sciences N.V. (ATAI) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4] Price Performance - ATAI shares have increased by 18.71% over the past week, significantly outperforming the Zacks Medical - Outpatient and Home Healthcare industry, which rose by 1.81% during the same period [6] - Over the past month, ATAI's stock price has risen by 32.03%, compared to the industry's 2.96% [6] - In the last quarter, ATAI shares increased by 22.42%, and over the past year, they gained 23.93%, while the S&P 500 experienced a decline of -2.55% and a modest increase of 11.45%, respectively [7] Trading Volume - The average 20-day trading volume for ATAI is 1,976,396 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, three earnings estimates for ATAI have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$0.75 to -$0.60 [10] - For the next fiscal year, two estimates have moved upwards, while one has been revised downwards [10] Conclusion - Given the strong price performance, positive earnings outlook, and high Momentum Style Score, ATAI is recommended as a solid momentum pick for investors [12]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Amedisys (AMED) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Amedisys is one of 997 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual ...

Group 1 - atai Life Sciences N.V. (ATAI) is outperforming its peers in the Medical sector with a year-to-date return of approximately 43.6%, while the average return for Medical companies is -6.3% [4] - The Zacks Rank for atai Life Sciences N.V. is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings outlooks [3] - The Zacks Consensus Estimate for ATAI's full-year earnings has increased by 0.8% over the past quarter, reflecting improved analyst sentiment [4] Group 2 - atai Life Sciences N.V. is part of the Medical - Outpatient and Home Healthcare industry, which ranks 84 in the Zacks Industry Rank, and this industry has an average year-to-date return of 3.7% [6] - Cardinal Health (CAH), another stock in the Medical sector, has a year-to-date return of 29.6% and also holds a Zacks Rank of 2 (Buy) [5] - The Medical - Dental Supplies industry, to which Cardinal Health belongs, is currently ranked 42 and has experienced a year-to-date decline of -1% [7]

Core Insights - Resmed has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia, highlighting its commitment to promoting sleep health in sports [1][3][6] Company Overview - Resmed is a leading health technology company focused on sleep, breathing, and home care, aiming to empower individuals to live healthier lives through innovative technologies [1][13] - The company operates in 140 countries and emphasizes the importance of quality sleep as a critical component of overall health [13] Campaign Details - The 'Tackle Your Sleep' campaign will feature legendary rugby players and aims to raise awareness about sleep health issues affecting both players and fans [3][5] - The campaign will provide advice and tools to improve sleep quality, emphasizing its significance alongside exercise and diet [3][5] Health Implications - Poor sleep can negatively impact mental and physical health, relationships, and daily performance, particularly for athletes [4][5] - A study indicated that half of the rugby and cricket players surveyed were classified as poor sleepers, with many experiencing significant daytime fatigue [4][5] Tour Information - The British & Irish Lions Tour will take place over six weeks, featuring matches in six cities across Australia, with an estimated 40,000 fans participating [2][8] - The Lions will play a total of 10 matches, including three Test matches against the Wallabies [8]

Rhythm Pharmaceuticals (RYTM) 2025 Conference May 14, 2025 12:20 PM ET Speaker0 Much for joining us. My name is Joanna Gajuk. I cover health care facilities managed care of America. Thanks so much for joining the conference and the session. So now a pleasure to to have Addus Home Care, so I'm pretty sure they would ask. They're one of the largest or maybe the largest provider of personal care services in The U. S, but they also do other things. We can talk about that. But today, we'd actually have an entire ...